Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

ndependence Group NL					
.BN 46 09	02 786 304				
Ve (tl	Ve (the entity) give ASX the following information.				
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).					
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Fully Paid Ordinary Shares			
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,323,614			
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares ranking equally with all other Fully Paid Ordinary Shares			

Name of entity

04/03/2013 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Consideration – zero The deemed issued price is \$4.09, being the 5 day VWAP up to and including 13 July 2015
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue on vest of Performance Rights.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	1,323,614	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	15 July 2015	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	235,580,187	Fully Paid Ordinary Shares

04/03/2013 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
112,602	Performance Rights vesting not earlier than 1 July 2015* (Note1).
368,059	Performance Rights vesting not earlier than 1 July 2016*.
509,840	Performance Rights vesting not earlier than 1 July 2017*.

Note 1 – Updated to reflect vesting of shares issued under this Appendix 3B. The remaining shares are still subject to vesting conditions.

\* Subject to vesting conditions.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) Rank equally with existing Fully Paid Ordinary Shares

#### Part 2 - Pro rata issue - N/A

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- Type of \*securities (tick one)
- (a) Securities described in Part 1
- (b) All other \*securities

  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities.

#### Entities that have ticked box 34(a)

- Same class as Fully Paid Ordinary Shares

Entities that have ticked box 34(b) – N/A

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

- The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those \*securities should not be granted \*quotation.
- An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 21 July 2015

Company Secretary Tony Walsh

Anthony Walsh

== == == ==

04/03/2013 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	234,256,573			
Add the following:				
<ul> <li>Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid *ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid *ordinary securities cancelled during that 12 month period</li> </ul>	1,323,614 ordinary shares both issued under an Employee incentive plan approved by shareholders in the last 3 years -			
"A"	235,580,187			

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

0. 0.0.1.1.4.7.5.4.7.				
Step 2: Calculate 15% of "A"				
"B"	0.15			
	[Note: this value cannot be changed]			
<b>Multiply</b> "A" by 0.15	35,234,303			
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used				
Insert number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Zero			
Under an exception in rule 7.2				
Under rule 7.1A				
With security holder approval under rule 7.1 or rule 7.4				
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>				
"C"	Zero			
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1				
"A" x 0.15	35,337,028			
Note: number must be same as shown in Step 2				
Subtract "C"	Zero			
Note: number must be same as shown in Step 3				
<b>Total</b> ["A" x 0.15] – "C"	35,337,028			
	[Note: this is the remaining placement capacity under rule 7.1]			

### Part 2 – N/A

o4/o3/2013 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.